Novavax jab to enter a big market, just not in the U.S. To view this email as a web page,
click here | | Webinar: New Trends in Virtual Trials Monday, July 26 | 11am ET / 8am PT Last year, clinical trial platform developer Medable raised $91M in private funding, amid the COVID-19 pandemic that touched off huge demand among pharma companies looking to initiate “siteless” or virtual clinical trials. Explore the role of CROs in siteless trials and the opportunities and challenges for CROs to expand their capabilities in this burgeoning area. Register now. |
Moderna banks $3.3B in latest COVID-19 vaccine supply deal with US, rounding out government’s earmarked doses Medicaid enrollment swells under pandemic, hitting nearly 74M Novavax's COVID-19 shot won't see much U.S. use, but a big global market awaits: analyst Moove over IPO: SAB Biotherapeutics to milk the stock market via SPAC Nursing home deaths spiked 32% among Medicare beneficiaries during 2020, OIG finds COVID-19 tracker: White House to miss July 4 vaccination goal; Delta variant 'greatest threat' to US response, Fauci says Sanofi, Translate Bio start seasonal mRNA flu vaccine trial, gaining early lead over Moderna and Pfizer Featured Story | By Noah Higgins-Dunn The U.S. will pay Moderna $3.3 billion for 200 million additional COVID-19 vaccine doses, as announced last week. That brings the country's total supply to 500 million, which is the amount Moderna earmarked for the U.S. back in August. read more |
| |
|---|
|
Top Stories By Paige Minemyer Medicaid enrollment grew significantly under the pandemic, according to new data from the Biden administration. read more By Kevin Dunleavy Because of development delays, Novavax should expect little uptake for its COVID-19 vaccine in the United States. But there's still a ready market globally, which the shot is well equipped to serve, GlobalData analysts report. read more By Amirah Al Idrus After grabbing government grants to develop its polyclonal antibody treatment for COVID-19, SAB Biotherapeutics is going public through a $118 million SPAC merger. The proceeds will bankroll a pipeline of treatments for various diseases that are produced by and extracted from genetically modified cows. read more By Dave Muoio More than 2 in 5 beneficiaries living in a nursing home were diagnosed with confirmed or likely COVID-19, with nonwhite and dual-eligible beneficiaries being hit the hardest, according to the government watchdog. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner The Biden administration said it will likely miss its goal of administering one dose of vaccine to 70% of adult Americans by the Fourth of July. And more headlines. read more By Nick Paul Taylor Sanofi and Translate Bio have started a phase 1 clinical trial of an mRNA vaccine for seasonal influenza. The initiation of the study puts the partners ahead of Moderna and Pfizer in the race to show mRNA vaccines are as good or better at preventing flu than existing technologies. read more | | Webinar: COVID-19 Virus Sequencing for Drug Development Wednesday, July 28 | 10:30am ET / 7:30am PT As new COVID-19 variants continue to emerge, virus sequencing will play critical and ongoing role in drug and vaccine development. This webinar will connect insights from population surveillance to potential solutions for drug developers, outline approaches to COVID-19 virus sequencing and more. Register Now. |
|
|
